nach oben

Drugs

Erschienen in:

01.04.2001 | Adis New Drug Profile

Levosimendan

verfasst von: David P. Figgitt, Peter S. Gillies, Karen L. Goa

Erschienen in: Drugs | Ausgabe 5/2001

Einloggen, um Zugang zu erhalten

Abstract

▴ Levosimendan, a pyridazinone-dinitrile derivative, is a calcium sensitiser with additional action on adenosine triphosphate (ATP)-sensitive potassium channels. It is used intravenously (IV) for the treatment of decompensated cardiac failure.
▴ At therapeutic doses, levosimendan exhibits enhanced contractility with no increase in oxygen demands. It also produces antistunning effects without increasing myocardial intracellular calcium concentrations or prolonging myocardial relaxation. Levosimendan also causes coronary and systemic vasodilation.
▴ In patients with decompensated congestive heart failure (CHF), IV levosimendan significantly reduced the incidence of worsening CHF or death.
▴ IV levosimendan significantly increased cardiac output or cardiac index and decreased filling pressure in the acute treatment of stable or decompensated CHF in large, double-blind, randomised trials and after cardiac surgery in smaller trials.
▴ Levosimendan is well tolerated, with the most common adverse events (headache, hypotension, nausea) being secondary to vasodilation. It has not been shown to be arrhythmogenic.
▴ Levosimendan has shown no clinically important pharmacokinetic interactions with captopril, felodipine, β-blockers, digoxin, warfarin, isosorbide-5-mononitrate, carvedilol, alcohol (ethanol) or itraconazole.

Steering Committee and Membership of the Advisory Council To Improve Outcomes Nationwide in Heart Failure (ACTION HF). Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999 Jan 21; 83 Suppl. 2A: 1–38

Oren RM, Pies CJ, Panther LM, et al. Therapeutic strategies for advanced heart failure. Cardiovasc Rev Rep 1997 Sep; 18: 21–7

McAlister FA, Teo KK. The management of congestive heart failure. Postgrad Med J 1997 Apr; 73: 194–200PubMedCrossRef

Garg R, Gorlin R, Smith T, et al. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997 February 20; 336(8): 525–33CrossRef

Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991 Nov 21; 325(21): 1468–75PubMedCrossRef

Haikala H, Nissinen E, Etemadzadeh E. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 1995 May; 25: 794–801PubMedCrossRef

Lancaster MK, Cook SJ. The effects of levosimendan on [Ca²⁺]_i in guinea-pig isolated ventricular myocytes. Eur J Pharmacol 1997 Nov 19; 339: 97–100PubMedCrossRef

Varró A, Papp JG. Classification of positive inotropic actions based on electrophysiologic characteristics: where should calcium sensitizers be placed? J Cardiovasc Pharmacol 1995; 26 Suppl. 1: 32–44

Lehtonen L. Levosimendan: a promising agent for the treatment of hospitalized patients with decompensated heart failure. Curr Cardiol Rep 2000; 2: 233–43PubMedCrossRef

10.

Hasenfuss G, Holubarsch H, Blanchard E, et al. Energetic aspects of inotropic interventions in rat myocardium. Basic Res Cardiol 1987; 82: 251–9PubMed

11.

Haikala H, Kaivola J, Nissinen E, et al. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995 Sep; 27: 1859–66PubMedCrossRef

12.

Levijoki J, Pollesello P, Kaivola J, et al. Further evidence for the cardiac troponin C mediated calcium sensitization by levosimendan: structure-response and binding analysis with analogs of levosimendan. J Mol Cell Cardiol 2000; 32: 479–91PubMedCrossRef

13.

Pollesello P, Ovaska M, Kaivola J, et al. Binding of a new Ca²⁺ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study [published erratum appears in J Biol Chem 1995 Feb 10; 270 (6): 2880]. J Biol Chem 1994 Nov 18; 269: 28584–90PubMed

14.

Sorsa T, Heikkinen S, Abbott MB, et al. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. J Biol Chem 2001; 276(12): 9337–43PubMedCrossRef

15.

Haikala H, Lindén I-B. Mechanisms of action of calcium-sensitizing drugs. J Cardiovasc Pharmacol 1995; 26 Suppl. 1: 10–9

16.

Hasenfuss G, Pieske B, Kretschmann B, et al. Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics. J Cardiovasc Pharmacol 1995; 26 Suppl. 1: 45–51

17.

Pagel PS, Harkin CP, Hettrick DA. Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs. Anesthesiology 1994 Oct; 81: 974–87PubMedCrossRef

18.

Hasenfuss G, Pieske B, Castell M, et al. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 1998 Nov 17; 98: 2141–7PubMedCrossRef

19.

Edes I, Kiss E, Kitada Y, et al. Effects of levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca²⁺ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 1995 Jul; 77: 107–13PubMedCrossRef

20.

Yokoshiki H, Katsube Y, Sunagawa M, et al. The novel calcium sensitizer levosimendan activates the ATP-sensitive K⁺channel in rat ventricular cells. J Pharmacol Exp Ther 1997 Oct; 283: 375–83PubMed

21.

Kaheinen P, Haikala H. Increases in diastolic coronary flow by levosimendan and pinacidil are differently mediated through opening of the ATP-sensitive potassium channels [abstract no. 1253]. J Am Coll Cardiol 1998 Apr; 31 Suppl. C: 154C

22.

Kaheinen P, Haikala H. Levosimendan and milrinone increase diastolic coronary flow through opening of the ATP-sensitive potassium channels by different mechanisms of action [abstract no. 1254] [abstract]. J Am Coll Cardiol 1998 Apr; 31 Suppl. C: 154C

23.

Pataricza J, Hohn J, Petri A, et al. Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J Pharm Pharmacol 2000; 52: 213–7PubMedCrossRef

24.

Bowman P, Haikala H, Paul R. Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J Pharmacol Exp Ther 1999 Jan; 288: 316–25PubMed

25.

Yokoshiki H, Katsube Y, Sunagawa M, et al. Levosimendan, a novel Ca²⁺ sensitizer, activates the glibenclamide-sensitive K⁺ channel in rat arterial myocytes. Eur J Pharmacol 1997 Aug 27; 333: 249–59PubMedCrossRef

26.

Gruhn N, Nielsen-Kudsk JE, Theilgaard S, et al. Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties. J Cardiovasc Pharmacol 1998 May; 31: 741–9PubMedCrossRef

27.

Haikala H, Kaheinen P, Levijoki J, et al. The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. Cardiovasc Res 1997 Jun; 34: 536–46PubMedCrossRef

28.

Bokník P, Neumann J, Kaspareit G, et al. Mechanisms of the contractile effects of levosimendan in the mammalian heart. J Pharmacol Exp Ther 1997 Jan; 280: 277–83PubMed

29.

Pagel PS, McGough MF, Hettrick DA, et al. Levosimendan enhances left ventricular systolic and diastolic function in conscious dogs with pacing-induced cardiomyopathy. J Cardiovasc Pharmacol 1997 May; 29: 563–73PubMedCrossRef

30.

Udvary É, Papp JG, Végh Á. Cardiovascular effects of the calcium sensitiser, levosimendan, in heart failure induced by rapid pacing in the presence of aortic constriction. Br J Pharmacol 1995 Feb; 114: 656–61PubMedCrossRef

31.

Du Toit EF, Muller CA, McCarthy J, et al. Levosimendan: effects of a clacium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart. J Pharmacol Exp Ther 1999; 290(2): 505–14PubMed

32.

Lochner A, Colesky F, Genade S. Effect of a calcium-sensitizing agent, levosimendan, on the postcardioplegic inotropic response of the myocardium. Cardiovasc Drugs Ther 2000; 14: 271–81PubMedCrossRef

33.

Janssen PML, Datz N, Zeitz O, et al. Levosimendan improves diastolic and systolic function in failing human myocardium. Eur J Pharmacol 2000; 404(1–2): 191–9PubMedCrossRef

34.

Sundberg S, Lilleberg J, Nieminen MS, et al. Hemodynamic and neurohumoral effects of levosimendan, a new calcium sensitizer, at rest and during exercise in healthy men. Am J Cardiol 1995 May 15; 75: 1061–6PubMedCrossRef

35.

Lilleberg J, Sundberg S, Häyhä M, et al. Haemodynamic dose-efficacy of levosimendan in healthy volunteers. Eur J Clin Pharmacol 1994; 47(3): 267–74PubMedCrossRef

36.

Lilleberg J, Sundberg S, Nieminen MS. Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction. J Cardiovasc Pharmacol 1995; 26 Suppl. 1: 63–9

37.

Lilleberg J, Nieminen MS, Akkila J, et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 1998 Apr; 19: 660–8PubMedCrossRef

38.

Follath F, Cleland JGF, Just H, et al. Efficacy and safety of intravenous levosimendan in severe low-output heart failure [abstract no. 3406]. Circulation 1999; 100(18) Suppl. I: I–646

39.

Nieminen MS, Akkila J, Hasenfuss G, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 1903–12PubMedCrossRef

40.

Slawsky MT, Colucci WS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000; 102: 2222–7PubMedCrossRef

41.

Ukkonen H, Saraste M, Akkila J, et al. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther 2001; 68: 522–31CrossRef

42.

Ukkonen H, Saraste M, Akkila J, et al. Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers. Clin Pharmacol Ther 1997 May; 61: 596–607PubMedCrossRef

43.

Harkin CP, Pagel PS, Tessmer JP, et al. Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs. J Cardiovasc Pharmacol 1995 Aug; 26: 179–88PubMedCrossRef

44.

Sonntag S, Opitz C, Wellnhofer E, et al. Effects of the calcium sensitizer levosimendan on stunned myocardium after percutaneous transluminal coronary angioplasty [abstract no. P387]. Eur Heart J 2000; 21 Suppl. Aug/Sep 2000: 40

45.

Givertz MM, Andreou C, Conrad CH. Direct myocardial effects of levosimendan, a novel calcium sensitizing agent, in humans with left ventricular dysfunction [abstract no. 3050]. Circulation 1998 Oct 27; 98 (17 Suppl.): 1–579CrossRef

46.

Rump AFE, Acar D, Rösen R, et al. Functional and antiischaemic effects of the phosphodiesterase inhibitor levosimendan in isolated rabbit hearts. Pharmacol Toxicol 1994 Apr–May; 74: 244–8PubMedCrossRef

47.

Rump AFE, Acar D, Klaus W. A quantitative comparison of functional and anti-ischaemic effects of the phosphodiesterase-inhibitors, amrinone, milrinone and levosimendan in rabbit isolated hearts. Br J Pharmacol 1994 Jul; 112: 757–62PubMedCrossRef

48.

Kersten JR, Montgomery MW, Pagel PS, et al. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of KATpchannels. Anesth Analg 2000; 90: 5–11PubMedCrossRef

49.

Orion Corporation. SIMDAX (levosimendan): Written summary to the clinical documentation. Espoo, Finland: Orion Corporation, 2000 May. (Data on file)

50.

Kusuoka H, Marban E. Cellular mechanisms of myocardial stunning. Annu Rev Physiol 1992; 54: 243–56PubMedCrossRef

51.

Jamali IN, Kersten JR, Pagel PS. Intracoronary levosimendan enhances contractile function of stunned myocardium. Anesth Analg 1997 Jul; 85: 23–9PubMed

52.

Lubbe WF, Podzuweit T, Opie LH. Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload: implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors. J Am Coll Cardiol 1992 June; 19(7): 1622–33PubMedCrossRef

53.

Kaszala K, Végh A, Udvary E, et al. Is levosimendan antiarrhythmic or arrhythmogenic? [abstract no. 329]. J Mol Cell Cardiol 1994; 26: LXXXIII

54.

Singh BN, Lilleberg J, Sandell E-P, et al. Effects of levosimendan on cardiac arrhythmia: electrophysiologic and ambulatory electrocardiographic findings in phase II and phase III clinical studies in cardiac failure. Am J Cardiol 1999; 83(12B): 16 (I)–20(I)

55.

Toivonen L, Viitasalo M, Sundberg S, et al. Electrophysiologic effects of a calcium sensitizer inotrope levosimendan administered intravenously in patients with normal cardiac function. J Cardiovasc Pharmacol 2000; 35(4): 664–9PubMedCrossRef

56.

Nicklas JM, Monsur JC, Bleske BE. Effects of intravenous levosimendan on plasma neurohormone levels in patients with heart failure: relation to hemodynamic response. Am J Cardiol 1999; 83(12B): 12(I)–5(I)

57.

Sandell EP, Häyhä M, Antila S, et al. Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure. J Cardiovasc Pharmacol 1995; 26 Suppl 1: S57–62PubMed

58.

Sundberg S, Antila S, Scheinin H, et al. Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals. Int J Clin Pharmacol Ther 1998 Dec; 36: 629–35PubMed

59.

Antila S, Järvinen A, Akkila J, et al. Studies on psychomotoric effects and pharmacokinetic interactions of the new calcium sensitizing drug levosimendan and ethanol. Arzneimittel Forschung 1997 Jul; 47: 816–20PubMed

60.

Lilleberg J, Antila S, Karlsson M, et al. Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers. Clin Pharmacol Ther 1994 Nov; 56: 554–63PubMedCrossRef

61.

Pentikäinen PJ, Antila S, Kivikko M, et al. Pharmacokinetics of levosimendan in patients with severe congestive heart failure [abstract no. 173]. J Card Fail 1999; 5 Suppl. 1

62.

Sandell EP, Antila S, Koistinen H, et al. The effects of renal failure on the pharmacokinetics of levosimendan [abstract no. 495]. 1st Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT); 1995 Sep 27–30; Paris

63.

Turanlahti M, Antila S, Rantanen S, et al. Pharmacokinetics and safety profile of levosimendan in pediatric patients evaluated for cardiac surgery [abstract no. 270]. Intensive Care Med 1999; 25 Suppl. 1: S72

64.

Sandell EP, Aalto T, Antila S, et al. The effects of severe congestive heart failure on the pharmacokinetics of levosimendan [abstract]. Eur J Clin Pharmacol 1997; 52 Suppl.: 55

65.

Antila S, Järvinen A, Honkanen T, et al. Pharmacokinetic and pharmacodynamic interactions between the novel calcium sensitiser levosimendan and warfarin. Eur J Clin Pharmacol 2000; 56(9–10): 705–10PubMedCrossRef

66.

Antila S, Honkanen T, Lehtonen L, et al. The CYP3A4 inhibitor itraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug levosimendan. Int J Clin Pharmacol Ther 1998 Aug; 36(8): 446–9PubMed

67.

Pagel PS, Haikala H, Pentikäinen PJ, et al. Pharmacology of levosimendan: a new myofilament calcium sensitizer. Cardiovasc Drug Rev 1996; 14(3): 286–316CrossRef

68.

Antila S, Huuskonen H, Nevalainen T, et al. Site dependent bioavailability and metabolism of levosimendan in dogs. Eur J Pharm Sci 1999; 9(1): 85–91PubMedCrossRef

69.

Takahashi R, Talukder MAH, Endoh M. Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium. Eur J Pharmacol 2000; 400: 103–12PubMedCrossRef

70.

Takahashi R, Talukder MAH, Endoh M. Effects of OR-1896, an active metabolite of levosimendan, on contractile force and aequorin light transients in intact rabbit ventricular myocardium. J Cardiovasc Pharmacol 2000; 36: 118–25PubMedCrossRef

71.

Nieminen MS, Moiseyev VS, Andrejevs N, et al. Randomized study on safety and effectiveness of levosimendan in patients with left ventricular failure after an acute myocardial infarction [abstract no. 3404]. Circulation 1999; 100 (18 Suppl. I): 1–646

72.

Nijhawan N, Nicolosi AC, Montgomery MW, et al. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol 1999; 34(2): 219–28PubMedCrossRef

73.

Lehtonen L, Mills-Owens P, Akkila J. Safety of levosimendan and other calcium sensitizers. J Cardiovasc Pharmacol 1995; 26 Suppl. l: S70–6PubMed

74.

Antila S, Eha J, Heinpalu M, et al. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril. Eur J Clin Pharmacol 1996; 49(6): 451–8PubMedCrossRef

75.

Lehtonen L, Antila S, Eha J, et al. No pharmacodynamic interactions between a new calcium sensitizing agent levosimendan and a calcium antagonist drug felodipine [abstract]. Eur J Clin Pharmacol 1997; 52 Suppl.: 136

76.

Antila S, Järvinen A, Honkanen T, et al. A new calcium sensitizing agent levosimendan has no pharmacokinetic or pharmacodynamic interactions with warfarin [abstract no. 382]. Eur J Clin Pharmacol 1997; 52 Suppl.: A128

77.

Sundberg S, Lehtonen L. Haemodynamic interactions between the novel calcium sensitiser levosimendan and isosorbide-5-mononitrate in healthy subjects. Eur J Clin Pharmacol 2000; 55: 793–9PubMedCrossRef

78.

Sundberg S, Lehtonen L. Hemodynamic interactions between levosimendan and carvedilol in healthy subjects. Orion Pharma; Report No.: 3001041; 2000 Apr 25. (Data on file)

79.

Orion Corporation. Orion launching proprietary medicine again. Simdax (levosimendan) approved in Sweden for severe heart failure. Media release [4 pages] 2000 Sep 26. Available from: URL: http://www.orionpharma.com [Accessed 2000 Oct 9]

Titel: Levosimendan
verfasst von: David P. Figgitt
Peter S. Gillies
Karen L. Goa
Publikationsdatum: 01.04.2001
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 5/2001
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200161050-00006

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2001

Achieving Optimal Outcomes in Chronic Lymphocytic Leukaemia

Bendamustine

Levosimendan

Bendamustine

Emerging Strategies in Infectious Diseases

Current Concepts on Pathophysiology, Diagnosis and Treatment of Diffuse Oesophageal Spasm